Abstract:BackgroundImmunologic memory against vaccine-preventable diseases is often lost after an allogeneic hematopoietic cell transplant (allo-HCT), therefore recipients are required to be re-immunized after allo-HCT to regain immunity against these infections. But the response to vaccination after an allo-HCT can be highly variable and is not well understood. We performed a single center retrospective study to examine immunization practices and determine the rate of vaccine protection and seroconversion following vaccination after allo-HCT.MethodsElectronic medical records (EMR) from patients ≤18 years of age who underwent allo-HCT at St. Jude Childrens' Research Hospital between 2005 - 2021 were reviewed. Clinical information and serology results before and after completion of the immunizations series were extracted from the EMR. The vaccines included in this analysis were diphtheria, measles, mumps, rubella (MMR), varicella, and polio. Protection was evaluated only for infections with established immune correlates. Seroconversion was defined as 4-fold increase in titers for vaccines with quantitative antibody assays, or as a change from negative to positive IgG for vaccines with qualitative antibody tests.Results760 patients were included in this cohort. Demographic and clinical data are summarized in Table 1. The mean age at allo-HCT was 10.4 years, most were male (56.8%) and white (74.6%). Acute leukemia accounted for 66.4% of allo-HCT recipients. Conditioning was myeloablative for 53.45%, and reduced intensity for 37.9%. Most received transplants from mismatched-related donors, (44.9%), followed by matched unrelated donors (35.4%) and matched related donors (19.5%). The number of patients who received the full vaccination series at our institution differed by vaccine and ranged from 41-150, and the respective subsets with available pre-vaccination and post-vaccination titers ranged from 24-93. The median time from transplant to initiation of immunizations was 12 months (range: 6-58) for non-live vaccines, 25 months (range: 23, 63) for MMR vaccine, and 28 months (range: 16, 117)) for varicella vaccine. Protection post immunization varied, with less patients demonstrating protections for mumps (79%) and measles (82%) (Figure 1). Seroconversion also varied among the different vaccine components and types of vaccines.ConclusionCurrent strategies to re-immunize patients after allo-HCT do not provide protection to all patients. Understanding the factors associated with suboptimal immune responses is critical for advancing our knowledge in this area. Whether time-based approaches combined with immune reconstitution data are required to further optimize protection remains unclear. Additionally, different vaccine schedules (i.e., higher doses) may be required in these patients.Table 1: Demographic and transplant characteristics Overall (N=760) Age at HSCT (years) Mean (SD)10.4 (6.16)Median [Min, Max]10.6 [0.0684, 27.2] Race White567 (74.6%)Black131 (17.2%)Asian23 (3.0%)Mixed18 (2.4%)Other16 (2.1%)Native American5 (0.7%) Gender Female328 (43.2%)Male432 (56.8%) Diagnosis ALL230 (30.3%)AML274 (36.1%)Myelodysplastic Syndrome33 (4.3%)Other leukemias/lymphomas66 (8.7%)Aplastic Anemia50 (6.6%)Sickle Cell Anemia24 (3.2%)Solid tumors18 (2.4%)Other conditions65 (8.6%) Conditioning Regimen Myeloablative406 (53.4%)Reduced Intensity288 (37.9%)No preparative regimen1 (0.1%)Missing65 (8.6%) Graft product type Peripheral Blood Derived Stem Cells391 (51.4%)Bone Marrow363 (47.8%)Missing6 (0.8%) Donor type Mismatched Related341 (44.9%)Matched Related148 (19.5%)Matched Unrelated269 (35.4%)Missing2 (0.3%) Figure 1. Protection and seroconversion rate by vaccine target.

Serologic evaluation of vaccine preventable infections and vaccination rates in kidney transplant candidates

Immunity Rates of Live Viral Vaccines in Pediatric Renal Transplant Candidates: A Single-Center Experience.

Incomplete Immunity for Varicella and Measles in Pediatric Organ Transplant Candidates. Real World Experience From an Infectious Diseases Pre‐Transplantation Clinic

Evaluating the antibody response to SARS-COV-2 vaccination amongst kidney transplant recipients at a single nephrology centre

SARS-CoV-2 Vaccination Rates and Uptake of Tixagevimab-Cilgavimab Among a Cohort of Pediatric Solid Organ Transplant Recipients

Varicella-Zoster Virus Pretransplant Vaccination and Posttransplant Infections Among Pediatric Solid Organ Recipients in the Two-Dose Varicella Era: A Single-Center, Multi-Organ Retrospective Study

Safety and infectious outcomes in pediatric kidney transplant recipients after COVID‐19 vaccination: A pediatric nephrology research consortium study

Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients

Safety and immunogenicity of the live-attenuated varicella vaccine in pediatric solid organ transplant recipients: A systematic review and meta-analysis

Antibody responses to re-immunization in recipients of allogeneic hematopoietic cell transplantation

Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice

COVID-19 Vaccination in Kidney Transplant Candidates and Recipients

Inter- and intra-individual differences regarding SARS-CoV-2 and influenza vaccination in pediatric kidney transplant recipients: An observational study

Tailoring cytomegalovirus prophylaxis based on T cell immunity panel assessment in kidney transplant patients at high risk of cytomegalovirus

Monitored COVID-19 vaccine humoral response in immunocompromised solid organ transplant recipients

A prospective study of the predictive value of polymerase chain reaction assay for cytomegalovirus in asymptomatic kidney transplant recipients

Optimizing SARS-CoV-2 vaccine responses in kidney transplant recipients: an urgent need

Burden and frequency of viral testing of kidney and non-kidney transplant recipients

Predictors of Serological Response to SARS-CoV-2 Vaccination in Kidney Transplant Patients: Baseline Characteristics, Immunosuppression, and the Role of IMPDH Monitoring

MO184: Development and Validation of a Multivariable Prediction Model for Nonseroconversion after SARS-COV-2 Vaccination in Kidney Transplant Recipients

Live‐attenuated vaccination for measles, mumps, and rubella in pediatric liver transplantation